Medicare coverage for Alpha-1 Antitrypsin Deficiency Disorder treatment.
The John W. Walsh Alpha-1 Home Infusion Act of 2025 amends title XVIII of the Social Security Act to provide coverage and payment for Alpha-1 Antitrypsin Deficiency Disorder treatment under Medicare Part B. This includes payment for intravenous administration kits and nursing services for up to 2 hours of care by a qualified home infusion therapy supplier. The act defines terms such as "augmentation therapy" and "qualified home infusion therapy supplier." The amendments apply to items and services furnished on or after January 1, 2027.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.